- Generic name
- Mirabegron
- Strength
- 25 mg
- Dosage form
- Er Tablet
- Manufactured by
- Advanced Chemical Industries PLC
Miragon 25 PR Er Tablet
About Miragon 25 PR Er Tablet
Miragon 25 PR 25 mg er tablet is a medicine made by Advanced Chemical Industries PLC. Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
There are 10 brands of Mirabegron listed in Bangladesh. The lowest listed price is Betmira ER 25 mg Tablet (Extended Release) at ৳ 30.00 per unit.
What is Miragon 25 PR Er Tablet?
Made by Advanced Chemical Industries PLC, Miragon 25 PR is a er tablet whose active ingredient is Mirabegron. Ask your doctor or pharmacist if you are unsure about it.
Uses of Miragon 25 PR
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Ask your doctor whether it is right for your condition.
How to use Miragon 25 PR
Miragon 25 PR is taken by mouth. Swallow the er tablet with water. Take Miragon 25 PR exactly as your doctor or pharmacist tells you. Do not change the dose or stop early without asking your doctor. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Miragon 25 PR
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Safety and precautions
Studies in animals have shown reproductive toxicity. Mirabegron should not be administered during breast-feeding. Mirabegron is not recommended during pregnancy and in women is planning to be pregnant. Ask your doctor first if any of these apply to you.
Frequently asked questions
What is Miragon 25 PR used for?
Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. Ask your doctor whether it is right for your condition.
How is Miragon 25 PR used?
Miragon 25 PR is taken by mouth. Swallow the er tablet with water.
What should I watch for while using Miragon 25 PR?
Contact your doctor if you notice anything unusual after taking it. Tell your doctor if any side effect bothers you or does not go away.
Who should be careful with Miragon 25 PR?
Studies in animals have shown reproductive toxicity. Mirabegron should not be administered during breast-feeding.
Indications
Pharmacology
Dosage & Administration
Renal or hepatic impairment:
- Patients with severe renal impairment (ClCr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B), the daily dose of Mirabegron should not exceed 25 mg tablet once daily.
- Mirabegron has not been studied in patients with end stage renal disease (GFR <15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child Pugh Class C) and it is therefore not recommended for use in these patient populations.
Paediatric population: The safety and efficacy of Mirabegron in children below 18 years of age have not yet been established.
Interaction
Effect of enzyme inducers: Substances that are inducers of CYP3A or P-gp decrease the plasma concentrations of Mirabegron. No dose adjustment is needed for Mirabegron when administered with therapeutic doses of rifampicin or other CYP3A or P-gp inducers.
Effect of Mirabegron on CYP2D6 substrates: In healthy volunteers, the inhibitory potency of Mirabegron towards CYP2D6 is moderate and the CYP2D6 activity recovers within 15 days after discontinuation of Mirabegron. Multiple once daily dosing of Mirabegron IR resulted in a 90% increase in Cmax and a 229% increase in AUC of a single dose of metoprolol. Multiple once daily dosing of Mirabegron resulted in a 79% increase in Cmax and a 241% increase in AUC of a single dose of desipramine. Caution is advised if Mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6, such as thioridazine, Type 1 C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine). Caution is also advised if Mirabegron is co-administered with CYP2D6 substrates that are individually dose titrated.
Effect of Mirabegron on transporters: Mirabegron is a weak inhibitor of P-gp. Mirabegron increased Cmax and AUC by 29% and 27%, respectively, of the P-gp substrate digoxin in healthy volunteers. For patients who are initiating a combination of Mirabegron and digoxin, the lowest dose for digoxin should be prescribed initially. Serum digoxin concentrations should be monitored and used for titration of the digoxin dose to obtain the desired clinical effect.
Other interactions: No clinically relevant interactions have been observed when Mirabegron was co-administered with therapeutic doses of solifenacin, tamsulosin, warfarin, metformin or a combined oral contraceptive medicinal product containing ethinylestradiol and levonorgestrel. Dose-adjustment is not recommended.
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
Hepatic impairment: Mirabegron has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and, therefore, it is not recommended for use in this patient population. Mirabegron is not recommended for use in patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A inhibitors.
Hypertension: Mirabegron can increase blood pressure. Blood pressure should be measured at baseline and periodically during treatment with Mirabegron, especially in hypertensive patients. Data are limited in patients with stage 2 hypertension (systolic blood pressure 160 mm Hg or diastolic blood pressure 100 mm Hg).
Patients with congenital or acquired QT prolongation: Caution should be exercised when administering Mirabegron in patients with congenital or acquired QT prolongation.
Patients with bladder outlet obstruction and patients taking antimuscarinics medications for OAB: A controlled clinical safety study in patients with bladder outlet obstruction (BOO) did not demonstrate increased urinary retention in patients treated with Mirabegron; however, Mirabegron should be administered with caution to patients with clinically significant bladder outlet obstruction. Mirabegron should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.
Overdose Effects
Storage Conditions
Alternative brands of Mirabegron
Other brands with the same generic name, cheapest first.
Betmira ER Tablet (Extended Release)
25 mg
Healthcare Pharmaceuticals Ltd.
৳ 29.4 ৳ 30.00 2% off per unit
Betmira ER Tablet (Extended Release)
50 mg
Healthcare Pharmaceuticals Ltd.
৳ 53.9 ৳ 55.00 2% off per unit
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.